The American Society of Clinical Oncology recommends the use of Oncotype Dx to guide the use of chemotherapy after surgery for patients with HR positive, HER2 negative early stage breast cancer, showing integration of multiple gene and protein expression biomarkers into clinical best practice recommendations for selection of therapeutics (Andre et al., 2019). This evidence concerns the gene ERBB2 and breast carcinoma.